传统的解热镇痛抗炎药主要以环氧合酶-2（COX-2）为靶点，在世界范围内拥有巨大的市场，虽几经改良，但仍存在较多副作用，一直没有良好的替代品。自1999年发现微粒体前列腺素E₂合成酶-1（mPGES-1)以来，部分目光敏锐的研究人员注意到这可能是解热镇痛抗炎药的一个新靶点。此后近10年时间内，人们就其生物化学、病理生理学特性进行了大量研究。然而，其药学方面的研究尚处于起始阶段，但国际制药公司已将其作为开发提高解热镇痛抗炎药的重要靶标。主要就mPGES-1抑制剂的研究进展作一简述。

Most antipyretic-analgesic and anti-inflammatroy drugs are COX-2 inhibitors. There is a huge market for antipyretic-analgesic and anti-inflammatory drugs. Although these drugs have some toxic and side effects, there is no better substitute for them. After the discovery of mPGES-1, rescarchers pay much attention to this novel target, and have done many studies on biochemical and pathophysiological as pects of mPGES-1. Nevertheless the strdies on pharmaceutical aspect of mPGES-1 are still in the intitial stage. It is promising to developing new mPGES-1 inhibitors.